Abbe Kirsch
Bronx, NYNPI 1215026927
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $120,268 of the $121,186 with a category attached, or 99.2%. Organon accounts for 99.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $46,907 and has fallen 82.9% since, to $8,044 in 2025.
Across 302 payments — averaging $401.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$121K
- Biogen$55
- Vertex$55
- Coopersurgical, Inc.$28
- Shield Therapeutics Inc$18
What the payments were for
- Speaking & faculty fees$120,26899%
- Travel & lodging$3270%
- Food & beverage$5910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 296 | $121,030 |
| Biogen | 2 | $55 |
| Vertex | 2 | $55 |
| Coopersurgical, Inc. | 1 | $28 |
| Shield Therapeutics Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXPLANON$101,866
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.